Cancer Vaccine Market Anticipates Robust Growth with a Projected 8.87% CAGR Through 2028
January 22, 2024 23:48 ET
|
Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Cancer Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to ResearchAndMarkets.com's...
New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presented
October 26, 2023 08:30 ET
|
Evaxion Biotech
Data from Evaxion’s two personalized cancer vaccine clinical trials to be presented at the annual meeting of the Society for Immunotherapy of Cancer (SITC)These new sets of clinical data further...
Global Neoantigen Cancer Vaccine Research Report 2023: An $8.872 Billion Market by 2031 - Growing at a Staggering CAGR of 69.4%
September 27, 2023 04:28 ET
|
Research and Markets
Dublin, Sept. 27, 2023 (GLOBE NEWSWIRE) -- The "Global Neoantigen Cancer Vaccine Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering. The global...
Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines
May 25, 2023 17:00 ET
|
Evaxion Biotech
Evaxion developed a genetic adjuvant technology that boosts the immune responses of viral, bacterial and cancer vaccinesPreclinically validated for both DNA and mRNA vaccines, and ready for clinical...
Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01
May 25, 2023 17:00 ET
|
Evaxion Biotech
Positive clinical response as demonstrated in 8 out of 12 patients receiving EVX-01 in combination with a checkpoint inhibitor The study met primary endpoints for tolerability and safety COPENHAGEN,...
Global Cancer Vaccines Competitive Landscape Report 2023: Comprehensive Insights About 250+ Companies and 300+ Drugs
May 03, 2023 07:08 ET
|
Research and Markets
Dublin, May 03, 2023 (GLOBE NEWSWIRE) -- The "Cancer Vaccines - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This "Cancer Vaccines - Competitive...
Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients
March 28, 2023 07:46 ET
|
Evaxion Biotech
New AI discovery de-risking the pipeline through faster validation and has potential to enter clinical Phase 1/2a in Q4 2023Phase 2b clinical trial reduced in size and expected to reach interim data...
Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)
March 14, 2023 16:30 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Evaxion receives FDA fast-track designation for personalized cancer immunotherapy
January 19, 2023 08:45 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01
January 03, 2023 07:30 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...